Literature DB >> 8473729

Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. I. Inhibition by RP-3 treatment of the priming and effector phases of delayed type hypersensitivity to sheep red blood cells in rats.

C Kudo1, T Yamashita, A Araki, M Terashita, T Watanabe, M Atsumi, M Tamura, F Sendo.   

Abstract

Recent studies on neutrophils have revealed that these cells produce various cytokines, and may be involved in regulation of the immune response. We examined whether neutrophils are involved in delayed type hypersensitivity (DTH) to SRBC in rats by selective depletion of in vivo neutrophils using a mAb designated RP-3. When the rats had been treated with RP-3 at the time of priming with SRBC, DTH to these cells was inhibited. Furthermore, RP-3 treatment was effective in inhibiting the effector phase of the DTH response to SRBC. When spleen cells from rats that had been treated with RP-3 at the time of immunization were used for local transfer of DTH, footpad swelling was significantly less than that induced by spleen cells from the RP-3-untreated immune rats.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473729

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Changing world of neutrophils.

Authors:  Csaba I Timár; Akos M Lőrincz; Erzsébet Ligeti
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

2.  Neutrophil expression of Fas ligand and perforin directs effector CD8 T cell infiltration into antigen-challenged skin.

Authors:  Danielle D Kish; Anton V Gorbachev; Neetha Parameswaran; Neetu Gupta; Robert L Fairchild
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

3.  Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine.

Authors:  O Pérez; M Lastre; J Lapinet; G Bracho; M Díaz; C Zayas; C Taboada; G Sierra
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo.

Authors:  D D Taub; M Anver; J J Oppenheim; D L Longo; W J Murphy
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  Immunologic adverse reaction associated with low-carbide metal-on-metal bearings in total hip arthroplasty.

Authors:  Panagiotis Aroukatos; Maria Repanti; Thomas Repantis; Vassiliki Bravou; Panagiotis Korovessis
Journal:  Clin Orthop Relat Res       Date:  2009-12-18       Impact factor: 4.176

6.  Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria.

Authors:  L Chen; Z Zhang; F Sendo
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  Expression of Th1/Th2 cytokine mRNA in peritoneal exudative polymorphonuclear neutrophils and their effects on mononuclear cell Th1/Th2 cytokine production in MRL-lpr/lpr mice.

Authors:  C Yu; K Sun; C Tsai; Y Tsai; S Tsai; D Huang; S Han; H Yu
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

8.  Role for macrophage inflammatory protein 2 (MIP-2), MIP-1alpha, and interleukin-1alpha in the delayed-type hypersensitivity response to viral antigen.

Authors:  Terrence M Tumpey; Robin Fenton; Sara Molesworth-Kenyon; John E Oakes; Robert N Lausch
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

Authors:  L P Seung; D A Rowley; P Dubey; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

10.  CD8 T cells producing IL-17 and IFN-gamma initiate the innate immune response required for responses to antigen skin challenge.

Authors:  Danielle D Kish; Xiaoxia Li; Robert L Fairchild
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.